These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 14643346)

  • 21. Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
    Thomas JB; Herault XM; Rothman RB; Atkinson RN; Burgess JP; Mascarella SW; Dersch CM; Xu H; Flippen-Anderson JL; George CF; Carroll FI
    J Med Chem; 2001 Mar; 44(6):972-87. PubMed ID: 11300879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective delta-opioid agonists.
    Trabanco AA; Pullan S; Alonso JM; Alvarez RM; Andrés JI; Boeckx I; Fernández J; Gómez A; Iturrino L; Janssens FE; Leenaerts JE; De Lucas AI; Matesanz E; Meert T; Steckler T
    Bioorg Med Chem Lett; 2006 Jan; 16(1):146-9. PubMed ID: 16236510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel ligands lacking a positive charge for the delta- and mu-opioid receptors.
    Schiller PW; Berezowska I; Nguyen TM; Schmidt R; Lemieux C; Chung NN; Falcone-Hindley ML; Yao W; Liu J; Iwama S; Smith AB; Hirschmann R
    J Med Chem; 2000 Feb; 43(4):551-9. PubMed ID: 10691681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.
    Le Bourdonnec B; Goodman AJ; Graczyk TM; Belanger S; Seida PR; DeHaven RN; Dolle RE
    J Med Chem; 2006 Dec; 49(25):7290-306. PubMed ID: 17149859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Na+ modulation, inverse agonism, and anorectic potency of 4-phenylpiperidine opioid antagonists.
    Emmerson PJ; McKinzie JH; Surface PL; Suter TM; Mitch CH; Statnick MA
    Eur J Pharmacol; 2004 Jun; 494(2-3):121-30. PubMed ID: 15212965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists.
    Blaney FE; Raveglia LF; Artico M; Cavagnera S; Dartois C; Farina C; Grugni M; Gagliardi S; Luttmann MA; Martinelli M; Nadler GM; Parini C; Petrillo P; Sarau HM; Scheideler MA; Hay DW; Giardina GA
    J Med Chem; 2001 May; 44(11):1675-89. PubMed ID: 11356103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the amino acid residues in the sixth transmembrane domains accessible in the binding-site crevices of mu, delta, and kappa opioid receptors.
    Xu W; Li J; Chen C; Huang P; Weinstein H; Javitch JA; Shi L; de Riel JK; Liu-Chen LY
    Biochemistry; 2001 Jul; 40(27):8018-29. PubMed ID: 11434771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor.
    Zhu J; Xue JC; Law PY; Claude PA; Luo LY; Yin J; Chen C; Liu-Chen LY
    FEBS Lett; 1996 Apr; 384(2):198-202. PubMed ID: 8612823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists.
    Carroll FI; Chaudhari S; Thomas JB; Mascarella SW; Gigstad KM; Deschamps J; Navarro HA
    J Med Chem; 2005 Dec; 48(26):8182-93. PubMed ID: 16366600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells.
    Hirota K; Okawa H; Appadu BL; Grandy DK; Devi LA; Lambert DG
    Anesthesiology; 1999 Jan; 90(1):174-82. PubMed ID: 9915326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
    Neumeyer JL; Zhang A; Xiong W; Gu XH; Hilbert JE; Knapp BI; Negus SS; Mello NK; Bidlack JM
    J Med Chem; 2003 Nov; 46(24):5162-70. PubMed ID: 14613319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.
    Maier CA; Wünsch B
    J Med Chem; 2002 Jan; 45(2):438-48. PubMed ID: 11784148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
    Metzger TG; Paterlini MG; Ferguson DM; Portoghese PS
    J Med Chem; 2001 Mar; 44(6):857-62. PubMed ID: 11300867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and in vitro opioid receptor functional antagonism of methyl-substituted analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).
    Cueva JP; Cai TB; Mascarella SW; Thomas JB; Navarro HA; Carroll FI
    J Med Chem; 2009 Dec; 52(23):7463-72. PubMed ID: 19954245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion of delta-, kappa- and mu-receptor selective opioid peptide agonists into delta-, kappa- and mu-selective antagonists.
    Schiller PW; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Lu Y
    Life Sci; 2003 Jun; 73(6):691-8. PubMed ID: 12801590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: development of a class of potent and highly delta-selective peptide antagonists.
    Schiller PW; Nguyen TM; Weltrowska G; Wilkes BC; Marsden BJ; Lemieux C; Chung NN
    Proc Natl Acad Sci U S A; 1992 Dec; 89(24):11871-5. PubMed ID: 1334552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
    Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
    J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor.
    Chen Z; Davies E; Miller WS; Shan S; Valenzano KJ; Kyle DJ
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5275-9. PubMed ID: 15454210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors.
    Zhang A; Xiong W; Bidlack JM; Hilbert JE; Knapp BI; Wentland MP; Neumeyer JL
    J Med Chem; 2004 Jan; 47(1):165-74. PubMed ID: 14695830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.